Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

http://www.wikidata.org/entity/Q53158136

about

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges Early Dementia Screening Alzheimer's Disease: Mechanism and Approach to Cell Therapy Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics Immunotherapy for Alzheimer's disease: hoops and hurdles Body fluid biomarkers in Alzheimer's disease Interaction between therapeutic interventions for Alzheimer's disease and physiological Aβ clearance mechanisms Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab Alzheimer's disease: Targeting the Cholinergic System Immunotherapeutic approaches for Alzheimer's disease 2012: the year in dementia.Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.Imaging endpoints for clinical trials in Alzheimer's disease.Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer.Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study.Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Amyloid-ß-directed immunotherapy for Alzheimer's disease.Novel immunological approaches for the treatment of Alzheimer's disease.Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study Vaccine-induced Aβ-specific CD8+ T cells do not trigger autoimmune neuroinflammation in a murine model of Alzheimer's disease.Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials Diffusion imaging changes in grey matter in Alzheimer's disease: a potential marker of early neurodegeneration.An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide.Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.Advances in the development of vaccines for Alzheimer's disease.Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology What does complement do in Alzheimer's disease? Old molecules with new insights.New Treatment for Alzheimer's Disease, Kamikihito, Reverses Amyloid-β-Induced Progression of Tau Phosphorylation and Axonal Atrophy.Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway

P2860

Q26745928-7F8B0B19-6208-4523-AE49-48305651EB00 Q26770171-0742F3DC-43FB-4907-B883-B4181F9341F9 Q26778149-6F4A8589-90E1-420A-A092-C3DCCF1EE1C8 Q26784569-0E734097-C069-486B-A9FE-A6A20C10576B Q26822002-838C959F-B406-47D7-A14C-999EED56109D Q26823877-441D0CFF-52E4-4F1B-AD49-7DD7D55A9766 Q26830098-89195B09-C611-433F-9881-6170D6132EF3 Q27001177-0C43A004-D76B-4692-A30B-A96C6437E784 Q27024824-120379F5-F9E8-44A7-A5DC-C6411D4BB769 Q27684692-3120546E-A265-4D95-9785-DFF5DE5726B2 Q28070135-69EDBF6B-55C9-42D3-8EE0-11E8689EA14F Q28081278-19D1047A-087C-47C0-9557-0D6B3CC4E98E Q30413415-8C6803E9-3A60-4CD1-80AF-1EC949113F81 Q30651551-C7FDB379-2E77-41FD-931A-4667362A1C8C Q30885979-0C36C3BA-AA35-4C7C-AFF6-17B95497E899 Q33604583-B4FD81D6-77C0-439B-8F92-BB74190CD085 Q33745617-386C7C09-4D1E-4D2D-AACE-8AF64DCC9A10 Q33746272-94090CC5-B76C-46D8-95CE-0E6CF90AE655 Q34039695-57AE8F26-C37D-40CF-93D4-CB92C0AA6CCE Q34064026-455AD63E-1F16-431A-9EA4-0559DDB9BBAC Q34376103-7B8D5B85-A1EE-4A1D-9EF6-38A990CF0657 Q34548700-74178181-D27F-4CE8-B5A3-E2CFA448F31B Q34562675-B6924460-B00D-45E8-B037-262A3E50E9C6 Q34974167-485116B5-5C69-46F3-8F21-B08DF7C37635 Q35115904-06127415-A4E0-4195-B65F-FD10E4730A2B Q35195612-0CC6FABB-79C9-4E59-A5E4-D6282311CFC8 Q35663042-4F622DB7-7A08-4ABF-8D46-810F48100448 Q35782753-9829C44C-D47A-43D4-85E7-BECB72B57F1A Q35806043-F3A9276C-03CB-4B7B-A866-AF2154686E3C Q35899066-713836F7-E3F1-4197-BD02-9236268BBF0F Q35972878-95A9637D-B48E-4DBA-8900-057ABB414254 Q35974386-C3BC453B-8C3A-4971-86E2-CBE0CB9E42B6 Q36269285-4B6412CC-A732-4239-B255-D3323F94D37A Q36484413-C3657EB1-4144-42DE-BE0A-F45D37603B75 Q36930444-0242DBBF-2091-46E5-A42D-628C4C492C00 Q36965988-2277B177-5BDF-40D1-910A-A57F60EFF217 Q37311364-5A1EFB12-F9F3-4955-B7CF-C5BF0F33A41F Q37368120-FC825DCA-919A-499E-B802-78E368E141B8 Q37636039-E4EC821F-3998-42FB-AB47-729B98244274 Q37652424-7C3182AC-C087-45A8-9EAE-95B24300C7DF

P2860

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

http://www.wikidata.org/entity/Q53158136

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

@en

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

@nl

type

label

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

@en

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

@nl

prefLabel

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

@en

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

@nl

P1433

Q53158136-820D977C-A198-4157-AFD6-84B7D9BBBD8C

P1476

Q53158136-588E88E4-1DE2-4D64-BF44-187EA31D937E

P2093

Q53158136-26988D39-3A38-4B0F-AC5D-3B72FB232B9A

Q53158136-353C6D7C-E148-45AF-831C-CC5F628B4A6D

Q53158136-5030AC74-2CDE-4CB7-A4A1-A9AB3BF6898A

Q53158136-5DDB89AA-73CE-4AE0-B4B5-6E593341DA23

Q53158136-6E5FF99D-7D57-4F70-B8B8-769907EAECA4

Q53158136-8FBD1A4F-87BD-4154-88E5-FF7612020C5B

Q53158136-9CCF424F-EFAD-4F32-B4FC-137A8CC9800C

Q53158136-AD06A25C-2772-4962-B5FC-21C74A279E07

Q53158136-C02B4DEB-B6F8-42CF-BBB6-3D0804FD1E93

Q53158136-C5FC294B-532F-4FAD-8B67-FA916241F5F3

P304

Q53158136-F59B5176-60A9-4AA3-A02B-6BDD30036D38

P31

Q53158136-C19FCAFA-C9C6-4C54-B1C1-45A3964B454E

P356

Q53158136-4F75CBAE-726F-4B9C-9259-379C3DB0DBEE

P433

Q53158136-FC528BC0-06F5-43F1-9D34-B02C942E416D

P478

Q53158136-9CAF97C2-442F-4248-82A4-AE122953872D

P50

Q53158136-8D5F5BFD-21B4-4892-B23C-9D8E98B21C2D

Q53158136-939CAB81-3600-4D4B-A95D-F7F7E71F5A6D

P577

Q53158136-AC3DE0D7-9D24-4718-96BE-40AA0B66C8A0

P5875

Q53158136-AD43776A-5D04-4587-A2E5-B3CA1054EB85

P698

Q53158136-6423E008-1B3E-489A-AF99-F23AB75E0C63

P921

Q53158136-8F2FA1E5-684C-4973-835C-2A9B8DCFB3A6

P356

J.JALZ.2011.09.224

P1433

Alzheimer's and Dementia

P1476

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

@en

P2093

Anton P Porsteinsson

http://www.w3.org/2001/XMLSchema#string

B Joy Snider

http://www.w3.org/2001/XMLSchema#string

Celedon Gonzales

http://www.w3.org/2001/XMLSchema#string

Christopher H van Dyck

http://www.w3.org/2001/XMLSchema#string

Eric R Siemers

http://www.w3.org/2001/XMLSchema#string

Gopalan Sethuraman

http://www.w3.org/2001/XMLSchema#string

Martin Farlow

http://www.w3.org/2001/XMLSchema#string

Richard Mohs

http://www.w3.org/2001/XMLSchema#string

Robert A Dean

http://www.w3.org/2001/XMLSchema#string

Ronald B DeMattos

http://www.w3.org/2001/XMLSchema#string

P304

261-271

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JALZ.2011.09.224

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Steven E. Arnold

P577

2012-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225277967

http://www.w3.org/2001/XMLSchema#string

P698

22672770

http://www.w3.org/2001/XMLSchema#string

P921